TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05283330: Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

Sponsor: Orano Med Theranostics, SAS · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 48 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$1,193,808

Rescue Site Savings

+$785,400

Unlock Full NCT05283330 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05283330 Rescue Dossier →